Strengthening the Value of Managed Care and Specialty Pharmacy for Successful Management of Hemophilia

Reserve your spot today for the Satellite Breakfast Symposium
Strengthening the Value of Managed Care and Specialty Pharmacy for Successful Management of Hemophilia


Jointly provided by
    Impact Education, LLC    
This activity is supported by independent educational grants from Alnylam Pharmaceuticals, Shire, Bayer HealthCare Pharmaceuticals, Grifols, and Novo Nordisk, Inc.

Wednesday, October 5, 2016
6:00 AM - 8:00 AM
Gaylord National Hotel & Convention Center
Room: Potomac C
National Harbor, MD
Held in conjunction with

AMCP Nexus 2016


Click here to download the slides from this symposium.

HOT TOPICS
  • Strategies used by managed care organizations (MCOs) and specialty pharmacy providers to facilitate high quality care
  • Impact of updated clinical recommendations for hemophilia, including prophylactic factor replacement and the role of emerging agents
  • Hemophilia-related complications associated with inhibitor development and its significant clinical and economic consequences
  • Opportunities to improve communications with HTCs
  • Methods for optimal cost management of factor replacement therapy
DISTINGUISHED FACULTY PRESENTERS
Edmund Pezalla, MD, MPH
Former National Medical Director, Pharmacy Policy and Strategy
Aetna
Vanita Pindolia, PharmD, BCPS
Vice President, Ambulatory Clinical Pharmacy Programs_PCM
Henry Ford Health System/Health Alliance Plan of Michigan
Steven Pipe, MD
Director, Division of Pediatric Hematology and Oncology
Pediatric Medical Director, Hemophilia and Coagulation Disorders Program
University of Michigan
Michael Zeglinski, RPh
Senior Vice President, Specialty Pharmacy
OptumRx®/BriovaRx®
WHO SHOULD ATTEND?

This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, members of AMCP, and other managed health care professionals attending AMCP Nexus 2016.

STATEMENT OF NEED / PROGRAM OVERVIEW

For health plans, treatment for patients with bleeding disorders, especially those with hemophilia, can be a tremendously heavy financial burden. The treatment of hemophilia ranks among the most expensive chronic diseases in the United States. New technology has led to remarkable advances in improving the safety of new blood products, but these technologies have come at ever-increasing costs. Total annual costs depend upon the severity of the disease and can average $250,000 or more for severe patients. Complications such as major surgery, undergoing immune tolerance for an inhibitor, HIV/AIDS, and/or hepatitis treatments, can increase these costs exponentially.

The high cost of clotting factor concentrates and the even higher cost of treatment of inhibitors makes hemophilia a potential target for cost-cutting efforts by various payers. Optimal outcomes for patients with hemophilia require a collaborative and coordinated patient experience. Representatives of the comprehensive care team, including a managed care medical director, managed care pharmacy director, specialty pharmacy expert, and a Hemophilia Treatment Center (HTC) clinician, will highlight important opportunities to optimize costs and improve patient care.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, participants should be able to demonstrate improved ability to:
  • Describe current and evolving strategies for managed care organizations (MCOs) and specialty pharmacy providers to facilitate high quality care for members with hemophilia
  • Cite the most recent clinical recommendations for the treatment of patients with hemophilia, including prophylactic factor replacement and the role of emerging agents
  • Explain hemophilia-related complications associated with inhibitor development and its significant clinical and economic consequences
  • Identify processes for MCOs and specialty pharmacy providers to improve communications with Hemophilia Treatment Centers (HTCs)
  • Apply methods to enable optimal cost management of factor replacement therapy to be realized by MCOs and specialty pharmacy providers
AGENDA

Date and Time
Wednesday, October 5, 2016
6:00 AM - 8:00 AM
Gaylord National Hotel & Convention Center
Room: Potomac C
National Harbor, MD

6:00 AM Opening Comments and Pre-activity Assessment
6:05 AM Medical Management Strategies to Integrate Hemophilia Care with Payer Policies
Edmund Pezalla, MD, MPH
6:25 AM Managing Patients with Inhibitors: Coordinated Care for Optimal Outcomes
Steven Pipe, MD
6:55 AM Moderated Faculty Panel Discussion
Faculty Panel
7:05 AM Optimizing the Pre-Certification and Prior Authorization Process
Vanita Pindolia, PharmD, BCPS
7:20 AM HTC and Specialty Pharmacy Collaboration: Steps for Success
Michael Zeglinski, RPh
7:45 AM Moderated Faculty Panel Discussion
Audience Question and Answer Session
Closing Comments
Post-activity Assessment and Evaluations
8:00 AM Adjournment
ACCREDITATION INFORMATION
Physician Continuing Medical Education
Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Education Resources (MER), National Hemophilia Foundation, and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources designates this live activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education
Accreditation Statement
Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


Credit Designation
MER designates this continuing education activity for 2.0 contact hours (0.20 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - 0816-9999-16-077-L01-P

Type of Activity: Knowledge


Disclosure of Conflicts of Interest
It is the policy of Medical Education Resources to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Impact Education, LLC, prior to the live event at (215) 619-8812.

Fee Information
Please note: No additional fee is required to attend this CPE/CME activity; however, registration to AMCP Nexus 2016 is required.

Pre-registration will close at 12:00 pm on October 4, 2016.
Walk-in registration will be available at the time of the program.
If you have any questions, please call (215) 619-8812 or email info@impactedu.net.

Register Now